Treatments & Services

Primarily indicated for degenerative knee osteoarthritis, addressing conditions such as cartilage wear and joint inflammation. The treatment employs a single intra-articular injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) to promote cartilage regeneration and suppress inflammatory responses.

In collaboration with Ruijin Hospital, Regend Therapeutics Limited has successfully applied its internationally leading autologous airway basal stem cell therapy to treat Chronic Obstructive Pulmonary Disease (COPD). This advanced treatment has achieved the reconstruction of functional blood-gas exchange units and the regenerative repair of damaged lung tissue.
Six months post-treatment, the first patient continues to show sustained clinical improvement, having successfully attained clinical remission

Targeting patients with chronic heart failure characterized by a Left Ventricular Ejection Fraction (LVEF) ≤ 40% and NYHA functional class II–IV. The study utilizes intravenous infusion of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) to promote myocardial microvascular neogenesis and reduce fibrosis

Regend Therapeutics' proprietary advanced therapy utilizing autologous airway basal stem cells is capable of reconstructing the epithelial barrier and significantly ameliorating the local immune-inflammatory microenvironment. Preliminary clinical studies conducted in collaboration with Ruijin Hospital demonstrated regenerative repair in damaged lung regions, as evidenced by CT imaging. Furthermore, patients exhibited marked improvements in quality of life and disease severity scores following treatment.

In patients with Interstitial Lung Disease (ILD), the disease progresses with pulmonary fibrosis and the destruction of healthy alveoli. The proprietary advanced therapy utilizing autologous airway basal stem cells facilitates the formation of novel alveolar and bronchial epithelial structures within weeks of administration. By reconstructing the epithelial barrier, this treatment effectively blocks fibroblast infiltration and collagen deposition, ultimately leading to enhanced pulmonary gas exchange function and significant clinical benefit for patients.

Indicated for severe Graft-versus-Host Disease (GvHD) following bone marrow transplantation. Administered via a single intravenous infusion, it utilizes allogeneic mesenchymal stem cells (MSCs) to modulate the immune response, eliminating the need for HLA matching.

Pulmonary fibrosis is a severe lung disease with limited current clinical treatment options and a poor prognosis for patients. Menstrual blood-derived mesenchymal stem cells (MenSCs) possess multipotent differentiation potential and immunomodulatory functions. Their application in treating pulmonary fibrosis aims to repair damaged lung tissue and modulate the pulmonary immune microenvironment, offering new hope for patients suffering from this condition.

Premature Ovarian Insufficiency (POI) severely compromises women's reproductive health and quality of life. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy holds promise for alleviating symptoms by improving the local ovarian microenvironment, promoting folliculogenesis, and restoring ovarian function.

Administered via localized minimally invasive injection, this therapy delivers human dental pulp mesenchymal stem cells (hDP-MSCs) to periodontal defect sites. Leveraging their biological advantages—including immunomodulation, osteogenesis, and angiogenesis—it promotes periodontal tissue regeneration, offering a novel therapeutic model and solution for the physiological and functional reconstruction of periodontal tissues.

Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy.

Stem cell therapy for rheumatoid arthritis focuses on addressing critical challenges in clinical treatment, featuring innovative technology based on umbilical cord-derived mesenchymal stem cells.